208 related articles for article (PubMed ID: 11049967)
1. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
Wierda WG; Cantwell MJ; Woods SJ; Rassenti LZ; Prussak CE; Kipps TJ
Blood; 2000 Nov; 96(9):2917-24. PubMed ID: 11049967
[TBL] [Abstract][Full Text] [Related]
2. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
3. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.
Kato K; Cantwell MJ; Sharma S; Kipps TJ
J Clin Invest; 1998 Mar; 101(5):1133-41. PubMed ID: 9486984
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.
Wierda WG; Castro JE; Aguillon R; Sampath D; Jalayer A; McMannis J; Prussak CE; Keating M; Kipps TJ
Leukemia; 2010 Nov; 24(11):1893-900. PubMed ID: 20882050
[TBL] [Abstract][Full Text] [Related]
5. CD154 gene therapy for human B-cell malignancies.
Messmer D; Kipps TJ
Ann N Y Acad Sci; 2005 Dec; 1062():51-60. PubMed ID: 16461788
[TBL] [Abstract][Full Text] [Related]
6. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.
Castro JE; Melo-Cardenas J; Urquiza M; Barajas-Gamboa JS; Pakbaz RS; Kipps TJ
Cancer Res; 2012 Jun; 72(12):2937-48. PubMed ID: 22505652
[TBL] [Abstract][Full Text] [Related]
7. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
Battle TE; Wierda WG; Rassenti LZ; Zahrieh D; Neuberg D; Kipps TJ; Frank DA
Clin Cancer Res; 2003 Jun; 9(6):2166-72. PubMed ID: 12796382
[TBL] [Abstract][Full Text] [Related]
8. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
9. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Hilchey SP; Halterman MW; Howard DF; Giuliano RE; Federoff HJ; Rosenblatt JD
Blood; 2001 Jul; 98(2):287-95. PubMed ID: 11435295
[TBL] [Abstract][Full Text] [Related]
10. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
[TBL] [Abstract][Full Text] [Related]
11. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
[TBL] [Abstract][Full Text] [Related]
12. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.
Okur FV; Yvon E; Biagi E; Dotti G; Carrum G; Heslop H; Mims MP; Fratantoni JC; Peshwa MV; Li L; Brenner MK
Cytotherapy; 2011 Oct; 13(9):1128-39. PubMed ID: 21745159
[TBL] [Abstract][Full Text] [Related]
14. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ
Leuk Lymphoma; 2000 May; 37(5-6):461-72. PubMed ID: 11042507
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Kater AP; Dicker F; Mangiola M; Welsh K; Houghten R; Ostresh J; Nefzi A; Reed JC; Pinilla C; Kipps TJ
Blood; 2005 Sep; 106(5):1742-8. PubMed ID: 15914559
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
18. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
19. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.
Li LH; Biagi E; Allen C; Shivakumar R; Weiss JM; Feller S; Yvon E; Fratantoni JC; Liu LN
Cancer Gene Ther; 2006 Feb; 13(2):215-24. PubMed ID: 16082377
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
